APR 20, 2019 10:39 PM PDT

The Microfluidic-Based Drug Screening Chip

WRITTEN BY: Nouran Amin

A team of researchers, at the Korea Advanced Institute of Science and Technology (KAIST), created a high throughput microfluidic-based drug screening chip that works to identify interactions between two antibiotics in eight hours. The screening chip can generate 121 pairwise concentrations and serve as a cell-based drug screening platform for surveying critical pharmacological patterns from these antibiotic interactions. The screening application can also be crucial for other cell-type agents and for use in clinical therapies.

Back cover image for the "Lab on a Chip". Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Current antibiotic susceptibility testing determines different types and doses of antibiotics that can block the growth of bacteria. Such testing has become critical with the rise of antibiotic resistance.

Overcoming antibiotic-resistant bacteria involves combination therapy of two or more kinds of antibiotics but, this kind of therapy is not always effective with the occasional unfavorable antibiotic pairs that result to suppressed antimicrobial effects.

The microfluidic-based drug screening chip will reduce time and enhance the efficiency of the combinatory testing. Using a sample volume of a few tens of microliters, the chip enabled 121 pairwise concentrations of two antibiotics to be formed in only 35 minutes.

Researchers used a mixture of bacteria and agarose and inserted into a microchannel. The mixture included injected reagents with or without antibiotics into the surrounding microchannel. The channel that had antibiotic molecules diffused into the channel without antibiotics and resulted in the formation of two orthogonal concentration gradients on the bacteria-trapping agarose gel.

Examples of testing results using the microfluidic chips developed in this research. Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Over a course of six hours, researchers were successful in microscopically observing the inhibition of bacterial growth by the antibiotic orthogonal gradients. The observations confirmed the different patterns of antibiotic pairs along with the different interaction types into either synergy or antagonism.

"The feasibility of microfluidic-based drug screening chips is promising, and we expect our microfluidic chip to be commercialized and utilized in near future,” says Professor Jessie Sungyun Jeon from the Department of Mechanical Engineering at KAIST.

Source: Phys.org

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 14, 2019
Drug Discovery
JAN 14, 2019
Vitamin D Proved Non-Beneficial for Individuals Aged 70 and Over
According to a study in the American Journal of Clinical Nutrition, researchers at Newcastle University have confirmed that older individuals, over the age...
FEB 27, 2019
Immunology
FEB 27, 2019
Anti-Inflammatory Meds without Side Effects, Please
Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide....
APR 21, 2019
Cell & Molecular Biology
APR 21, 2019
Getting Rid of Damaged Mitochondria Relieves Autoimmune Disease in Mice
Scientists have found a way to inhibit inflammatory molecules that are linked to diseases like lupus and osteoarthritis....
APR 24, 2019
Drug Discovery
APR 24, 2019
Nanomachine Improves Drug Delivery for Cancer Therapeutics
Recent studies on mice has allowed researchers to find a way to deliver specific drugs to certain parts of the body that are exceptionally difficult to acc...
MAY 21, 2019
Drug Discovery
MAY 21, 2019
New Viable Drug Target for Prostate Cancer
In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell...
MAY 23, 2019
Drug Discovery
MAY 23, 2019
Miracle Drug for Rare Genetic Disease Causes Price Concerns
A newly approved “miracle drug” called Zolgensma will be used to treat children with spinal muscular atrophy, or SMA. Unfortunately, the therap...
Loading Comments...